Werewolf Therapeutics (HOWL) Earnings Date & Reports

Key Takeaways

• Werewolf Therapeutics is expected to report third-quarter 2026 results in early November, covering the three months ended September 30, 2026.
• Wall Street consensus points to a net loss of approximately $0.22 per share for Q3 2026, narrower than the $0.36 per-share loss reported in the same period a year ago.
• Revenue expectations are less clearly defined because the company's top line is milestone-driven under its collaboration agreement with Jazz Pharmaceuticals.
• In the prior quarter (Q2 2026), Werewolf posted earnings per share (EPS) of $0.08, beating the consensus estimate of a $0.28 loss by $0.36, alongside revenue of $21 million.
• Investors will be watching cash runway, spending on the WTX-124 and WTX-330 clinical programs, and any update on collaboration milestone timing.
• For more details on Werewolf Therapeutics' Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages linked here.
• Discover how automated strategies are approaching this and similar setups by exploring Trending AI Robots.

Earnings Context and Why It Matters

Werewolf Therapeutics is a clinical-stage immuno-oncology company developing conditionally activated "INDUKINE" molecules designed to stimulate the immune system against cancer. Because it has no approved products, its quarterly results are less about sales growth and more about capital efficiency, pipeline advancement, and collaboration milestones. The company's collaboration with Jazz Pharmaceuticals has historically generated the bulk of its recognized revenue, meaning top-line figures can swing sharply depending on milestone timing. For investors, the upcoming report offers a checkpoint on clinical progress for lead candidates WTX-124 and WTX-330, the pace of research and development spending, and whether the company's cash position remains sufficient to fund its plans.

Earnings Expectations

Analysts expect Werewolf Therapeutics to report a net loss of approximately $0.22 per share for Q3 2026, which would mark an improvement from the $0.36 per-share loss recorded in the third quarter of 2025. Consensus revenue estimates appear less consistent, reflecting the milestone-dependent nature of the company's collaboration with Jazz Pharmaceuticals. In the second quarter of 2026, Werewolf surprised investors with EPS of $0.08 versus an expected loss of $0.28, accompanied by revenue of $21 million, which was widely attributed to collaboration milestone recognition.

Given this pattern, the headline EPS and revenue figures may not tell the whole story. Investors will likely focus on operating expenses, cash and equivalents, and management commentary on trial enrollment and data timing for WTX-124 and WTX-330. The stock has a history of sharp post-earnings moves, so volatility heading into the print is a key consideration.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking names like Werewolf Therapeutics, it offers a structured way to surface relevant setups across the biotech landscape.

Market Reaction and Investor Sentiment

Sentiment heading into Werewolf Therapeutics' Q3 2026 report reflects the stock's high volatility and its dependence on clinical and collaboration catalysts. The company's shares have experienced outsized moves around prior earnings releases, with milestone-driven revenue surprises occasionally driving pronounced reactions. As a clinical-stage biotech with a relatively small market capitalization, HOWL tends to be sensitive to changes in liquidity, development timelines, and broader risk appetite in the healthcare sector. Key risk factors include potential trial delays, higher-than-expected spending, and uncertainty around future collaboration milestones, all of which could weigh on investor confidence regardless of headline results.

Forward Outlook and Key Factors to Monitor

Beyond the Q3 2026 print, investors should watch several forward-looking items tied to the company's clinical pipeline and financial position.

First, progress on WTX-124 and WTX-330 remains central to the investment thesis. Updates on patient enrollment, safety data, and anticipated data readouts will likely matter more than quarterly figures alone. Any changes to development timelines could influence how the market values the company's programs.

Second, the collaboration with Jazz Pharmaceuticals is a key financial driver. Because revenue recognition is tied to milestone achievement, future quarters could see significant variability in the top line depending on when and whether additional milestones are triggered.

Third, cash runway and spending discipline deserve attention. As a company with no product revenue, Werewolf Therapeutics relies on its balance sheet and partnership economics to fund operations. Investors will likely monitor research and development expenses and management's comments on how long current cash is expected to last.

Finally, broader conditions in the biotechnology and immuno-oncology sectors, including financing conditions and investor appetite for early-stage names, may shape sentiment around HOWL in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations